tradingkey.logo

TherapeuticsMD Inc

TXMD
View Detailed Chart
2.290USD
+0.100+4.57%
Close 02/06, 16:00ETQuotes delayed by 15 min
26.50MMarket Cap
87.50P/E TTM

TherapeuticsMD Inc

2.290
+0.100+4.57%
Intraday
1m
30m
1h
D
W
M
D

Today

+4.57%

5 Days

+6.02%

1 Month

+12.25%

6 Months

+107.24%

Year to Date

+40.49%

1 Year

+126.73%

View Detailed Chart

TradingKey Stock Score of TherapeuticsMD Inc

Currency: USD Updated: 2026-02-06

Key Insights

TherapeuticsMD Inc's fundamentals are relatively very healthy, with an industry-leading ESG disclosure.and its growth potential is high.Its valuation is considered fairly valued, ranking 118 out of 159 in the Pharmaceuticals industry.Institutional ownership is very high.In the medium term, the stock price is expected to trend up.The company has been performing well in the stock market over the past month, which is supported by its strong fundamentals and technicals.The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.

TherapeuticsMD Inc's Score

Industry at a Glance

Industry Ranking
118 / 159
Overall Ranking
380 / 4521
Industry
Pharmaceuticals

Support & Resistance

Relevant data have not been disclosed by the company yet.

Score Analysis

Current score
Previous score

Media Coverage

Last 24 hours
Coverage Level

Very Low
Very High
Negative

TherapeuticsMD Inc Highlights

StrengthsRisks
TherapeuticsMD, Inc. is a pharmaceutical royalty company, which primarily collects royalties from its licensees. It receives royalties on products licensed to pharmaceutical organizations that possess commercial capabilities in the relevant territories. It granted a license to commercialize IMVEXXY, BIJUVA, and prescription prenatal vitamin products sold under the BocaGreenMD and vitaMedMD brands and assigned its exclusive license to commercialize ANNOVERA to Mayne Pharma. IMVEXXY (estradiol vaginal inserts) pharmaceutical product is for the treatment of moderate-to-severe dyspareunia. BIJUVA pharmaceutical product is a Food and Drug Administration (FDA)-approved bioidentical hormone therapy combination of estradiol and progesterone in a single, oral capsule for the treatment of moderate-to-severe vasomotor symptoms due to menopause in women with a uterus. ANNOVERA pharmaceutical product is a one-year ring-shaped contraceptive vaginal system (CVS).
Growing
The company is in a growing phase, with the latest annual income totaling USD 1.76M.
Overvalued
The company’s latest PE is 87.50, at a high 3-year percentile range.
Institutional Selling
The latest institutional holdings are 3.33M shares, decreasing 0.64% quarter-over-quarter.
Held by The Vanguard
Star Investor The Vanguard holds 397.06K shares of this stock.

Analyst Rating

Based on 0 analysts
--
Current Rating
--
Target Price
--
Upside Space
Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

TherapeuticsMD Inc News

More news coming soon, stay tuned...

Financial Indicators

EPS

Relevant data have not been disclosed by the company yet.

Total revenue

Relevant data have not been disclosed by the company yet.

TherapeuticsMD Inc Info

TherapeuticsMD, Inc. is a pharmaceutical royalty company, which primarily collects royalties from its licensees. It receives royalties on products licensed to pharmaceutical organizations that possess commercial capabilities in the relevant territories. It granted a license to commercialize IMVEXXY, BIJUVA, and prescription prenatal vitamin products sold under the BocaGreenMD and vitaMedMD brands and assigned its exclusive license to commercialize ANNOVERA to Mayne Pharma. IMVEXXY (estradiol vaginal inserts) pharmaceutical product is for the treatment of moderate-to-severe dyspareunia. BIJUVA pharmaceutical product is a Food and Drug Administration (FDA)-approved bioidentical hormone therapy combination of estradiol and progesterone in a single, oral capsule for the treatment of moderate-to-severe vasomotor symptoms due to menopause in women with a uterus. ANNOVERA pharmaceutical product is a one-year ring-shaped contraceptive vaginal system (CVS).
Ticker SymbolTXMD
CompanyTherapeuticsMD Inc
CEOWalker (Marlan D)
Websitehttps://www.therapeuticsmd.com/
KeyAI